Clinical and bacteriological effects of pivmecillinam for ESBL-producing escherichia coli or klebsiella pneumoniae in urinary tract infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 769-772

  Jansåker, Filip ^a   Frimodt Møller, Niels ^a   Sjögren, Ingegerd ^b   knudsen, Jenny Dahl ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Hallands Hospital Halmstad   (Sweden)

Author keywords

Antimicrobal therapy; Community acquired infections; Enterobacteriaceae; Mecillinam; Multidrug resistance

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; PIVMECILLINAM;

ADULT; AGED; DENMARK; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOLLOW UP; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIOLOGY; MIDDLE AGED; NETHERLANDS; PATHOLOGY; QUESTIONNAIRE; SECRETION (PROCESS); SWEDEN; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; URINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMDINOCILLIN PIVOXIL; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DENMARK; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; NETHERLANDS; QUESTIONNAIRES; SWEDEN; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; URINE; YOUNG ADULT;

EID: 84894088675     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt404     Document Type: Article

References (20)

1. Graninger W. Pivmecillinam-therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 2003; 22 Suppl 2: 73-8.
2. Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 Suppl 1: 35-9; discussion 63-5.
3. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
4. Auer S,Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-β-lactamaseproducing Escherichia coli. Antimicrob Agents Chemother 2010; 54: 4006-8.
5. Fournier D, Chirouze C, Leroy J et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect 2013; 43: 62-6.
6. Hansen DS, Schumacher H, Hansen F et al. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance. Scand J Infect Dis 2012; 44: 174-81.
7. Titelman E, Iversen A, Kahlmeter G et al. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 2011; 119: 853-63.
8. Tarnberg M, Ostholm-Balkhed A, Monstein HJ et al. In vitro activity of b-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2011; 30: 981-7.
9. Wootton M, Walsh TR, Macfarlane L et al. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2010; 65: 79-81.
10. Lampri N, Galani I, Poulakou G et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 2012; 67: 2424-8.
11. Frimodt-Møller N, Lundberg CV, Henriksen AS. Mecillinam is active against ESBL-CTX-M producing E. coli in vivo in experimental UTI. In: Abstracts of the Eighteenth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, 2008. Abstract P1917. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
12. Titelman E, Iversen A, Kalin M et al. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2012; 18: 189-92.
13. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters-Version 3.1. 2013. http://www.eucast.org/fileadmin/src/ media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf (26 September 2013, date last accessed).
14. Neuner EA, Sekeres J, Hall GS et al. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012; 56: 5744-8.
15. Pullukcu H, Tasbakan M, Sipahi OR et al. Fosfomycin in the treatment of extended spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-5.
16. Rodriguez-Bano J, Alcala JC, Cisneros JM et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
17. Tasbakan MI, Pullukcu H, Sipahi ORet al. Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents 2012; 40: 554-6.
18. Madani Y, Mann B. Nitrofurantoin-induced lung disease and prophylaxis of urinary tract infections. Prim Care Respir J 2012; 21: 337-41.
19. Schito GC,Naber KG,Botto H et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34: 407-13.
20. Gales AC, Sader HS, Jones RN et al. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002; 44: 289-99.